Cargando…

FNDC4 Inhibits RANKL-Induced Osteoclast Formation by Suppressing NF-κB Activation and CXCL10 Expression

FNDC4 acts as an anti-inflammatory factor on macrophages and improves mouse model of induced colitis. Considering osteoclast formation is characterized by the activation of inflammation-related pathways, we thus speculated that FNDC4 may play a pivotal role in this process. RT-qPCR analysis was perf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Zheng-tao, Liang, Shuang, Chen, Kun, Zhang, Jia-ming, Cheng, Peng, Guo, Jia-chao, Yang, Qing, Zhou, Chen-he, Liao, Hui, Chen, An-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998196/ https://www.ncbi.nlm.nih.gov/pubmed/29977911 http://dx.doi.org/10.1155/2018/3936257

Ejemplares similares

Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation
por: Wu, Lili, et al.
Publicado: (2019)

Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT
por: Hong, Guoju, et al.
Publicado: (2017)

Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation
por: Qin, Shengnan, et al.
Publicado: (2015)

Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption by suppressing MAPK, NF-κB and AKT signalling pathways and promotes Caspase3-mediated apoptosis of mature osteoclasts
por: Yan, Liuliu, et al.
Publicado: (2019)

Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways
por: Yuan, Yu, et al.
Publicado: (2020)

MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12
por: Lian, Wei-Shiung, et al.
Publicado: (2019)

Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-κB and NFAT Pathways
por: Zhou, Lin, et al.
Publicado: (2015)

TRAF Family Member-Associated NF-κB Activator (TANK) Induced by RANKL Negatively Regulates Osteoclasts Survival and Function
por: Wu, Mengrui, et al.
Publicado: (2012)

Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
por: Hu, Zi’ang, et al.
Publicado: (2018)

Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1–Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis
por: Fang, Ke, et al.
Publicado: (2022)

Recombinant Human Endostatin Suppresses Mouse Osteoclast Formation by Inhibiting the NF-κB and MAPKs Signaling Pathways
por: Chen, Nong, et al.
Publicado: (2016)

Magnolol Inhibits Osteoclast Differentiation via Suppression of RANKL Expression
por: Hwang, Youn-Hwan, et al.
Publicado: (2018)

Serum amyloid A inhibits RANKL-induced osteoclast formation
por: Oh, Eunseo, et al.
Publicado: (2015)

The effects of vasoactive intestinal peptide on RANKL-induced osteoclast formation
por: Qu, Hongyi, et al.
Publicado: (2021)

Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells
por: Kim, Jeong-Mi, et al.
Publicado: (2017)

A Medium-Chain Fatty Acid, Capric Acid, Inhibits RANKL-Induced Osteoclast Differentiation via the Suppression of NF-κB Signaling and Blocks Cytoskeletal Organization and Survival in Mature Osteoclasts
por: Kim, Hyun-Ju, et al.
Publicado: (2014)

NRROS Negatively Regulates Osteoclast Differentiation by Inhibiting RANKL-Mediated NF-κB and Reactive Oxygen Species Pathways
por: Kim, Jung Ha, et al.
Publicado: (2015)

IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling
por: Kim, Inyoung, et al.
Publicado: (2021)

The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation
por: Liu, Fei-Lan, et al.
Publicado: (2017)

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
por: Li, Xuedong, et al.
Publicado: (2021)

Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss
por: Liu, Huijiang, et al.
Publicado: (2022)

Erratum to: Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells
por: Kim, Jeong-Mi, et al.
Publicado: (2017)

Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling
por: Li, Shangfu, et al.
Publicado: (2016)

MicroRNA-26a Regulates RANKL-Induced Osteoclast Formation
por: Kim, Kabsun, et al.
Publicado: (2015)

Serum Insufficiency Induces RANKL-Independent Osteoclast Formation during Developing Ischemic ONFH
por: Hsiao, Yi-min, et al.
Publicado: (2021)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-κB activation
por: Bak, Sun-Uk, et al.
Publicado: (2017)

Retinoic Acid Increases Proliferation of Human Osteoclast Progenitors and Inhibits RANKL-Stimulated Osteoclast Differentiation by Suppressing RANK
por: Hu, Lijuan, et al.
Publicado: (2010)

Suppressive effects of (-)-tubaic acid on RANKL-induced osteoclast differentiation and bone resorption
por: Lim, Soomin, et al.
Publicado: (2023)

DCIR suppresses osteoclastic proliferation and resorption by downregulating M-CSF and RANKL signaling
por: Kaifu, Tomonori, et al.
Publicado: (2023)

TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation
por: Marahleh, Aseel, et al.
Publicado: (2019)

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation
por: He, Wenxin, et al.
Publicado: (2022)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021)

IDO1 facilitates esophageal carcinoma progression by driving the direct binding of NF-κB and CXCL10
por: Yao, Wenjian, et al.
Publicado: (2023)

Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro
por: Wang, Chuandong, et al.
Publicado: (2017)

Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss
por: Xiong, Jinhu, et al.
Publicado: (2018)

RO4929097 regulates RANKL-induced osteoclast formation and LPS-mediated bone resorption
por: Huang, Tao, et al.
Publicado: (2021)

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities
por: Joung, Youn Hee, et al.
Publicado: (2016)

Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways
por: Li, Xiucheng, et al.
Publicado: (2021)

Sinomenine Suppresses Osteoclast Formation and Mycobacterium tuberculosis H37Ra-Induced Bone Loss by Modulating RANKL Signaling Pathways
por: Li, Xiaojuan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dsrdb427mgvj7ma9mnnqenkdef